Atezolizumab (Tecentriq®) was the first FDA-approved immunotherapy for treating locally advanced or metastatic triple-negative breast cancer (TNBC). It is for treating breast cancer that tests positive for PD-L1 and is given along with the chemotherapy Abraxane® (nab-paclitaxel).
In March 2019, the FDA granted accelerated approval to atezolizumab based on Phase 3 IMpassion130 trial. Those trial results showed that atezolizumab improved progression-free survival for MBC patients.
This accelerated approval, however, was contingent on the results of the follow-up IMpassion131 trial. Unfortunately, IMpassion131 failed to show statistically meaningful survival benefits for people with metastatic TNBC when given atezolizumab.
Read the following articles to understand what has happened with Tecentriq® (Atezolizumab) and find trials studying how immunotherapy can help people with MBC.
Recent Update about Atezolizumab
- Medpage Today Genentech Pulls Atezolizumab’s Breast Cancer Approval
- Genentech Press Release Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
- Metastatic Trial Talk First Immunotherapy Approved for MBC
Clinical Trials for Immunotherapy
- Metastatic Trial Search Trials that Include Immunotherapy